Dova Pharmaceuticals, Inc. (DOVA) financial statements (2020 and earlier)

Company profile

Business Address 240 LEIGH FARM ROAD
DURHAM, NC 27707
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments6810595
Cash and cash equivalents6810595
Receivables11 
Inventory, net of allowances, customer advances and progress billings54 
Inventory54 
Prepaid expense 11
Other undisclosed current assets32 
Total current assets:7711296
Noncurrent Assets
Property, plant and equipment100
Other undisclosed noncurrent assets1  
Total noncurrent assets:200
TOTAL ASSETS:7911296
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities13135
Accounts payable211
Accrued liabilities11123
Interest and dividends payable001
Debt2730
Due to related parties 00
Other undisclosed current liabilities0 0
Total current liabilities:151935
Noncurrent Liabilities
Long-term debt and lease obligation 14 
Long-term debt, excluding current maturities 14 
Liabilities, other than long-term debt02 
Contract with customer, liability02
Other undisclosed noncurrent liabilities30  
Total noncurrent liabilities:3116 
Total liabilities:463635
Stockholders' equity
Stockholders' equity attributable to parent337661
Common stock000
Additional paid in capital217206118
Accumulated deficit(184)(129)(57)
Total stockholders' equity:337661
TOTAL LIABILITIES AND EQUITY:7911296

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
Revenues1410 
Cost of revenue
(Cost of Goods and Services Sold)
(2)(1) 
Gross profit:129 
Operating expenses(87)(81)(29)
Other undisclosed operating income21 
Operating loss:(73)(71)(29)
Nonoperating income
(Other Nonoperating income)
110
Interest and debt expense(3)(2)(1)
Loss before gain (loss) on sale of properties:(74)(72)(30)
Other undisclosed net loss  (0)
Net loss available to common stockholders, diluted:(74)(72)(30)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
Net loss:(74)(72)(30)
Comprehensive loss, net of tax, attributable to parent:(74)(72)(30)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: